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AN-AEA11A is frequently observed in cancer patients and also in animals bearing transplantable or induced tumours this association is the subject of a recent review by Price and Cxreenfield (1958) . It Berlin, Lawrence and Lee (1954) in leukaemia. Hyman, Gellhorn and Harvey (1956) , using both the Ashby technique and the transfusion of cells labelled with 51Cr found an increased rate of destruction of cells transfused from normal donors to patients with carcinomata and other neoplasms, whereas cells transfused from cancer patients to normal volunteers had a normal or near-normal life span. Hence they argued the absence of any intrinsic defect in the red cells of cancer patients. Miller, Chodos, Emerson and Ross (1956) also demonstrated by the Ashby and the 5ICr-techniques an increased rate of destruction of red cells transfused from normal subjects to patients with cancer of various sites or autotransfused to such patients.
The results of studies on animals bearing transplantable or induced tumours have been more conflicting. Ultman, Fish and Hyman (1956) , in studies of 5ICr-survival in rabbits bearing the Brown-Pearce or X112 carcinoma, failed to reveal any increased destruction of red cells except in animals with severe infection.
Ehrenstein (1958) used glycine-2-14C to study the life span of the circulating red cells in mice bearing the Ehrlich ascites carcinoma and found increased red cell dest-ruction of the random type in tumour-bearing animals. Greenfield, Godfrey and Price (1958) (Belcher, 1958 (Belcher, . 1959 Studie8 with5l6'r-labelled red ce118
Red cell survival studies with 5'Cr were made as described by Belcher and Harriss (1959) . In order to reduce the possibility of uncontrolled transfusion reactions, transfusion of blood was carried out under aseptic conditions between male litter mates, one member of each litter acting as donor, the others as recipients. In studies with 5ICr, the red cells of donor animals were labelled in vitro with 5'Cr as follows: 2 ml. of blood were withdrawn by cardiac puncture into a syringe containing 0-1 ml. heparin (" Pularin (Belcher and Harriss, 1957) .
Studies of 51Cr-distribution in the tissues were made as described by Belcher, Lamertoii and Harriss (195, S blood samples were taken from the cut tails of the recipient animals as already described, haemolysed in 5 ml. ammoniated distilled water and transferred to ' 8 5 inch diameter sample tubes for radioactive assay. To suppress re-utilisation of 59Fe from destroyed red cells by the erythropoietic tissues daily injections of 0-1 ml./100 g. body weight of an iron-dextran complex (" linferon ", Bengers Laboratories Ltd.) containing 50 mg. /ml. Fe were given intramuscularly throughout studies of red cell survival of 59Fe-labeHed cells.
In the radioactive assay of samples in single tracer experiments with 5ICr or 59Fe alone, the discriminator/analyser unit was operated as a simple discriminator. In double tracer experiments with 5'Cr and 59Fe, samples were first assayed for "We by using the unit as a discriminator set at a level such that the system was almost completely insensitive to 5'Cr. Samples were then assayed for 5'Cr using accompanied by haemoglobinuria and which may be fatal, the haemoglobin concentration of the circulating blood falls to about 5 g.1100 ml. (Fig. 1 11--l. to litter mate recipients (Fig. 6) . Despite the daily injection of iron-dextran to block re-utilisation, some of the 59Fe from destroyed red ceRs is incorporated into the haemoglobin of red cell precursors in the erythropoietic tissues and thus returned to the circulation during the haemolytic episode. For Sites of destruction of red cells from tumour-bearing donors labelled with 5'Cr and transfused to tumour-bearing recipients To identify the chief Siteg of red cell destruction during the haemolytic episode, red cells from tumour-bearing donors were labelled with 5'Cr and transfused to tumour-bearing recipients before the development of haemolysis. During or after the subsequent episode, recipient animals were sacrificed and exsanguinated. Fig. 7-10 show the results of experiments in which blood was taken from tumour-bearing donors at 4, 9, 14 and 19 days after implantation of tumour and labelled with -51Cr ; 0-5 ml. of the labelled red cell suspension or of the supernatant plasma was then trangfused intfavenously to normal litter inate recipients. When transfusion of red cells is carried out at 4 days after implantation, at which time the growing tumour is scarcely palpable (Fig. 7) , the haemolytic episode is preceded by a period of normal survival of the labelled cells. During the episode, both the transfused ceRs and the donor's own circulating red cells are destroyed simultaneously. Cells transfused at 9 days, shortly before the donor's own haemolytic episode (Fig. 8) , cause a more prompt haemolysis, though a period of normal survival can still be seen. At 14 days (Fig. 9) , haemolysis in the recipient is almost immediate and frequently fatal.
When transfusion of ceRs is carried out at 19 days after implantation, however, when the donor is in recovery (Fig. IO) Table 11 . With dilution, the haemolytic activity of the donor's blood is progressively reduced, as measured by the interval between transfusion and the onset of haemolysis, but even at a dilution of x 1000, a haemolytic episode is still observed. This dilution corresponds to the transfusion of only 0-0005 ml. of blood.
The data of Fig. 7 -10 may now be reconsidered in the light of these dilution studies. Table III summarises the results of those experiments in which 0-5 ml. animals previously transfused did not fail to produce the expected pattern of haemolysis.
Such protection has been found to extend at least up to two months after the initial haemolytic response. It has already been described how labelled red cells transfused from a tumour-bearing donor which has undergone its haemolytic episode to a normal recipient have a normal or near-normal survival (Fig. 10) . although a haemolytic episode is induced in the recipient. This is a further example of the protection afforded to the red cells of an animal that has undergone a haemolytic episode. 
DISCUSSION
In the abserice of the results of serological studies which are still incomplete, detailed discussion of the mechanisms underlying the phenomena described must be speculative. However, it is clear that the haemolytic episode and anaemia observed after implantation of the tumour R 2426 do not resemble that described by Greenfield and his co-workers, since no accumulation of 51Cr in the tumour is observed after transfusion of -5'Cr-labelled red cells.
The haemolytic episode has some features in common with those observed in auto-immune haemolytic anaemias attributed to the presence of incomplete warm agglutinins (Dacie, 1954; Jandl, Jones and Castle, 1957) Green, Wakefield and Littlerwood (1958) . In either of these situatioiis, the induction of haemolysis in a normal animal receiving a transfusion of blood from a tumour-bearing donor would be due to the transfer of antibody from the donor's red ceRs to those of the recipient. However it appears improbable that sufficient antibody could be transferred by such a mechanism to cause the haemolysis of nearly all the host's cells.
A further possibility is that the tumour might produce an antigen similar or complementary to antigenic components on the host"s red cells. Antibodies produced by the host against this antigen might then induce agglutination of the red cells. The antigen could be transferred with the blood of a tumour-bearing donor to a normal recipient and induce a similar production of antibody and agglutinatioli of the recipient's red cells. However, the finding that-the time between transfusion and onset of the haemolytic episode may be as little as two days does not seem to be compatible with such a mechanism.
The observations that the haemolytic activity of the blood increases steadily with time after implantation of tumour and that a haemolytic episode can follow the transfusion of minute amounts of blood from a tumour-bearing donor to a normal recipient suggest that the responsible agent is some factor, possibly viral in nature, which is capable of multiplication within the host. If such is the case, the question must be asked whether the virus is the causative agent of the tumour or whether it exists concomitantly in the tumour tissue but without aetiological relationship to it (Zilber, 1958) . Further studies designed to test all of these possibilities are being carried out.
SUMMARY
Rats of the " August " strain bearing the transplantable adenocarcinoma R 2426 undergo an acute haemolytic episode 10-15 days after implantation of tumour. This phenomenon has been investigated by radioactive tracer techniques with 5'Cr and 59Fe. Cells are destroyed randomly without regard to age during the haemolytic episode. Destroyed red cells accumulate primarily in the liver and spleen, destruction in the vascular bed of the tumour being absent or extremely small.
A similar haemolytic episode may be induced in normal animals transfused intravenously or intraperitoneally, with blood from tumour-bearing litter-mate donors. The rapidity of onset of the episode is related to the amount of blood transfused and to the time after implantation at which the blood is taken from the donor.
After an initial haemolytic episode induced by implant or transfusion, it is impossible to induce a second episode in the same animal; furthermore, red cells from a tumour-bearing donor which has suffered a haemolytic episode show nearnormal survival when transfused to normal recipients, although they provoke a haemolytic episode in the recipient.
The mechanisms by which these phenomena are brought about are discussed. 
